Broadly neutralizing antibodies (bnAbs) against HIV

Broadly neutralizing antibodies (bnAbs) against HIV

A review collection published in Retrovirology
Edited by Rogier Sanders and Marit van Gils.​​​​​​​

Since the discovery of HIV-1 as the causative virus of AIDS over 35 years ago, scientists have tried to stop the virus spreading through the human population by generating a protective vaccine. Early optimism that a vaccine would be available within 10 years soon changed into frustration and disappointment. However, the discovery of broadly neutralizing antibodies (bNAbs) fueled new optimism. The isolation and characterization of many new bNAbs over the last decade has changed the field by guiding the design of novel vaccine immunogens using bNAbs as templates and therapeutic approaches by exploiting the bNAbs themselves.​​​​​​​

This thematic series in Retrovirology contains a collection of review articles that describe bNAb development after HIV-1 infection, the application of bNAbs as therapeutics and the attempts to elicit bNAbs by vaccination.  

This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The Guest Editors declare no competing interests.

View all collections published in Retrovirology

1. Content Type:Review

   The expanding array of HIV broadly neutralizing antibodies

   A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and described, particularly in the last decade. This continually expanding array of bnAbs has crucially led to the identi...

   Authors:Laura E. McCoy

   Citation:Retrovirology 2018 15:70

   Published on: 16 October 2018

   • ViewFull Text
    
   • ViewPDF
2. Content Type:Review

   Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1

   Vectored gene delivery of HIV-1 broadly neutralizing antibodies (bNAbs) using recombinant adeno-associated virus (rAAV) is a promising alternative to conventional vaccines for preventing new HIV-1 infections a...

   Authors:Allen Lin and Alejandro B. Balazs

   Citation:Retrovirology 2018 15:66

   Published on: 1 October 2018

   • ViewFull Text
    
   • ViewPDF
3. Content Type:Review

   Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies

   An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV-1 antibodies (bNAbs) in order to be efficacious. The many bNAbs that have been isolated from HIV-1 infected patients ...

   Authors:Alba Torrents de la Peña and Rogier W. Sanders

   Citation:Retrovirology 2018 15:63

   Published on: 12 September 2018

   • ViewFull Text
    
   • ViewPDF
4. Content Type:Review

   Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers

   Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viruses, are a major focus of HIV vaccine design, with data from animal studies confirming their ability to prevent HIV in...

   Authors:Elise Landais and Penny L. Moore

   Citation:Retrovirology 2018 15:61

   Published on: 5 September 2018

   • ViewFull Text
    
   • ViewPDF
5. Content Type:Review

   Engineering multi-specific antibodies against HIV-1

   As increasing numbers of broadly neutralizing monoclonal antibodies (mAbs) against HIV-1 enter clinical trials, it is becoming evident that combinations of mAbs are necessary to block infection by the diverse ...

   Authors:Neal N. Padte, Jian Yu, Yaoxing Huang and David D. Ho

   Citation:Retrovirology 2018 15:60

   Published on: 29 August 2018

   • ViewFull Text
    
   • ViewPDF
6. Content Type:Review

   Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies

   Anti-HIV-1 broadly neutralizing antibodies (BnAbs) exhibit an impressive capacity to protect against chimeric SIV-HIV (SHIV) challenges in macaques and potently reduce viremia in both SHIV-infected macaques an...

   Authors:Matthew S. Parsons, Amy W. Chung and Stephen J. Kent

   Citation:Retrovirology 2018 15:58

   Published on: 22 August 2018

   • ViewFull Text
    
   • ViewPDF
7. Content Type:Review

   The role of follicular helper CD4 T cells in the development of HIV-1 specific broadly neutralizing antibody responses

   The induction of HIV-1-specific antibodies that can neutralize a broad number of isolates is a major goal of HIV-1 vaccination strategies. However, to date no candidate HIV-1 vaccine has successfully elicited ...

   Authors:Eirini Moysi, Constantinos Petrovas and Richard A. Koup

   Citation:Retrovirology 2018 15:54

   Published on: 6 August 2018

   • ViewFull Text
    
   • ViewPDF
8. Content Type:Review

   Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design

   A central puzzle in HIV-1 research is the inability of vaccination or even infection to reliably elicit humoral responses against broadly neutralizing epitopes in the HIV-1 envelope protein. In infected indivi...

   Authors:Joel Finney and Garnett Kelsoe

   Citation:Retrovirology 2018 15:53

   Published on: 28 July 2018

   • ViewFull Text
    
   • ViewPDF
9. Content Type:Review

   HIV-1 cell-to-cell transmission and broadly neutralizing antibodies

   HIV-1 spreads through contacts between infected and target cells. Polarized viral budding at the contact site forms the virological synapse. Additional cellular processes, such as nanotubes, filopodia, virus a...

   Authors:Jérémy Dufloo, Timothée Bruel and Olivier Schwartz

   Citation:Retrovirology 2018 15:51

   Published on: 28 July 2018

   • ViewFull Text
    
   • ViewPDF
10. Content Type:Review

    Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

    The elicitation of broadly neutralizing antibodies (bnAbs) is considered crucial for an effective, preventive HIV-1 vaccine. Led by the discovery of a new generation of potent bnAbs, the field has significantl...

    Authors:Harini Subbaraman, Merle Schanz and Alexandra Trkola

    Citation:Retrovirology 2018 15:52

    Published on: 28 July 2018

    • ViewFull Text
     
    • ViewPDF